Trial Profile

Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Liver metastases; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Aug 2023 Status changed from active, no longer recruiting to completed.
19 Apr 2023 Results assessing potential biomarkers in peripheral blood to predict response presented at the 114th Annual Meeting of the American Association for Cancer Research
12 Jan 2023 Planned primary completion date changed from 15 Jun 2023 to 15 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com